Piper Sandler Maintains Overweight on Acrivon Therapeutics, Raises Price Target to $30
Portfolio Pulse from Benzinga Newsdesk
Piper Sandler analyst Joseph Catanzaro has maintained an Overweight rating on Acrivon Therapeutics (NASDAQ:ACRV) and increased the price target from $26 to $30.
April 25, 2024 | 12:53 pm
News sentiment analysis
Sort by:
Ascending
POSITIVE IMPACT
Piper Sandler has maintained an Overweight rating on Acrivon Therapeutics and raised the price target from $26 to $30.
The increase in price target by a reputable analyst firm like Piper Sandler typically signals a positive outlook on the company's future performance, potentially leading to increased investor confidence and a rise in stock price in the short term.
CONFIDENCE 95
IMPORTANCE 90
RELEVANCE 100